1. |
Maraia RJ, Mattijssen S, Cruz-Gallardo I, et al. The La and related RNA-binding proteins (LARPs): structures, functions, and evolving perspectives. Wiley Interdiscip Rev RNA, 2017, 8(6): 10.1002/wrna.1430.
|
2. |
Wolin SL, Cedervall T. The La protein. Annu Rev Biochem, 2002, 71: 375-403.
|
3. |
Sommer G, Dittmann J, Kuehnert J, et al. The RNA-binding protein La contributes to cell proliferation and CCND1 expression. Oncogene, 2011, 30(4): 434-444.
|
4. |
Tang J, Zhang ZH, Liu GL. A systematic analysis of the predicted human La protein targets identified a hepatitis B virus infection signature. J Viral Hepat, 2013, 20(1): 12-23.
|
5. |
Tang J, Huang ZM, Chen YY, et al. A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation. PLoS One, 2012, 7(4): e36363.
|
6. |
Tong S, Pan J, Tang J. Study on the structure optimization and anti-hepatitis B virus activity of novel human La protein inhibitor HBSC11. J Med Virol, 2019, 91(10): 1818-1829.
|
7. |
Stavraka C, Blagden S. The La-related proteins, a family with connections to cancer. Biomolecules, 2015, 5(4): 2701-2722.
|
8. |
Mura M, Hopkins TG, Michael T, et al. LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene, 2015, 34(39): 5025-5036.
|
9. |
Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumorinfil-trating immune cells. Nucleic Acids Res, 2020, 48(W1): W509-W514.
|
10. |
Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res, 2017, 77(21): e108-e110.
|
11. |
Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol, 2016, 17(1): 174.
|
12. |
Kechavarzi B, Janga SC. Dissecting the expression landscape of RNA-binding proteins in human cancers. Genome Biol, 2014, 15(1): R14.
|
13. |
Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell, 2012, 149(6): 1393-1406.
|
14. |
陈昆仑, 吴怡, 李牧, 等. RNA 结合蛋白 La 在宫颈癌组织中的表达及临床意义. 南方医科大学学报杂志, 2013, 33(7): 999-1003.
|
15. |
Egiz M, Usui T, Ishibashi M, et al. La-related protein 4 as a suppressor for motility of ovarian cancer cells. Tohoku J Exp Med, 2019, 247(1): 59-67.
|
16. |
Kato M, Goto Y, Matsushita R, et al. MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer. Int J Oncol, 2015, 47(2): 710-718.
|
17. |
Xu Z, Xu J, Lu H, et al. LARP1 is regulated by the XIST/miR-374a axis and functions as an oncogene in non-small cell lung carcinoma. Oncol Rep, 2017, 38(6): 3659-3667.
|
18. |
Koso H, Yi H, Sheridan P, et al. Identification of RNA-binding protein LARP4B as a tumor suppressor in glioma. Cancer Res, 2016, 76(8): 2254-2264.
|
19. |
Ji X, Lu H, Zhou Q, et al. LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. Elife, 2014, 3: e02907.
|
20. |
Sommer G, Rossa C, Chi AC, et al. Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PLoS One, 2011, 6(10): e25402.
|
21. |
Xie C, Huang L, Xie S, et al. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J Transl Med, 2013, 11: 272.
|
22. |
Ye L, Lin ST, Mi YS, et al. Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target. Tumour Biol, 2016, 37(11): 14585-14594.
|
23. |
黄理宾, 陈海宁, 杨廷翰, 等. 胃癌的免疫治疗. 中国普外基础与临床杂志, 2019, 26(7): 779-784.
|
24. |
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell, 2010, 141(1): 39-51.
|
25. |
De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell, 2013, 23(3): 277-286.
|
26. |
Cianciaruso C, Beltraminelli T, Duval F, et al. Molecular profiling and functional analysis of macrophage-derived tumor extracellular vesicles. Cell Rep, 2019, 27(10): 3062-3080.
|
27. |
Al-Ejeh F, Darby JM, Brown MP. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs. Clin Cancer Res, 2007, 13(18 Pt 2): 5509s-5518s.
|